CI-994, Free Base (Acetyldinaline; Goe 5549; GÀÜ 5549; PD 123654; Tacedinaline; CAS 112522-64-2), >99%

LC Laboratories' Product Number C-2606 - CI-994, Free Base (Acetyldinaline; Goe 5549; G√Ä√ú 5549; PD 123654; Tacedinaline; CAS 112522-64-2), >99% - for research use only. CI-994 is a histone deacetylase (HDAC) inhibitor and induces histone hyperacetylation in living cells. CI-994 inhibited HDAC-1 and HDAC-2 but not the prototypical histone acetyltransferase GCN5. CI-994 in combination with traditional anti-cancer agents cytarabine (ara-C), daunorubicin and mitoxantrone resulted in a synergistic effect against acute myeloid leukemia (AML). CI-994 is a novel antitumor agent and had activity against 8 solid tumors tested including pancreatic ductal adenocarcinoma #02, pancreatic adenocarcinoma #03, colon adenocarcinoma #38, colon adenocarcinoma #51, mammary adenocarcinoma #25, mammary adenocarcinoma #17/ADR, Dunning osteogenic sarcoma and the human prostate carcinoma LNCaP. CI-994 inhibited the growth of two non-small cell lung cancer (NSCLC) cell lines, A-549 (adenocarcinoma) and LX-1 (squamous cell carcinoma), with an IC50 of 80 µM. It also showed synergism with standard anticancer agents such as gemcitabine and docetaxel.

• Supplier: LC Laboratories
• Product #: C-2606
• Sku #: C-2606_300mg